Brief: Bioxytran To Internally Develop Novel Carbohydrate Galectin Inhibitor To Eliminate Covid-19 In Patients
30/03/2020 19:04
March 30 (Reuters) - Bioxytran Inc BIXT.PK :
* BIOXYTRAN TO INTERNALLY DEVELOP NOVEL CARBOHYDRATE
GALECTIN
INHIBITOR TO ELIMINATE COVID-19 IN PATIENTS
Source text for Eikon: ID:nGNX37P8yG
Further company coverage: BIXT.PK
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on Bioxytran
See all newsUS officials pressed China on rare earths, farm goods commitments, Bessent says (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Brief: Bioxytran Inc Reports Positive Phase 1B/2A Clinical Study Results For Prolectin-M, Broad-Range Antiviral Drug In Mild To Moderate Covid-19
Brief: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran